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Oxidative modification of low-density lipoprotein (LDL) and
its deleterious effect on endothelium is implicated in the
pathogenesis of atherosclerosis. Endothelium responds to
such an insult by upregulating the synthesis of heme
oxygenase-1 (HO-1) and ferritin. Endothelial cell damage and
dysfunction have been observed in patients with chronic
kidney disease (CKD) on maintenance hemodialysis (HD). We
studied the effect of low-molecular-weight components of
uremic plasma on LDL oxidation and LDL-oxidation-provoked
endothelial cell reactions, such as the induction of
cytotoxicity and the upregulation of cell-protective HO-1 and
ferritin. Plasma ultrafiltrate (molecular weighto5000 Da)
from CKD patients on HD or when treated conservatively
exhibited a pronounced inhibition on heme-mediated
oxidative modification of LDL. Endothelial cell cytotoxicity
provoked by LDL oxidation was also attenuated by plasma
ultrafiltrate from CKD patients. During HD treatment, a
dramatic drop occurred in the retardation of oxidative
reactions, and a loss of endothelial cytoprotection exerted by
plasma ultrafiltrate was noted. The upregulation of HO-1 and
ferritin in response to oxidative stress of LDL was blunted by
uremic plasma ultrafiltrate that was released by the end of
HD. The decreased antioxidant capacity of ultrafiltrate after
HD occurred as a consequence of the intradialytic removal of
L-ascorbic acid, uric acid, bilirubin, 3-indoxyl sulfate,
indoxyl-b-D-glucuronide, p-cresol, and phenol. Intradialytic
removal of L-ascorbic acid, uric acid, bilirubin, 3-indoxyl
sulfate, indoxyl-b-D-glucuronide, p-cresol, and phenol
increases the risk of LDL oxidation and subsequent
endothelial cell damage, which underlines the importance of
activation of cytoprotective HO-1 and ferritin in endothelium.
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Oxidative modification of low-density lipoprotein (LDL) is a
key event in the pathogenesis of atherosclerosis.1 Metabolic
products of endothelial cells, smooth muscle cells, and
monocytes/macrophages can oxidize LDL, in which transi-
tion metals may serve as catalysts. Heme-catalyzed oxidation
of LDL may be one of the relevant mechanisms involved in
LDL modification.2–5 Oxidized LDL (ox-LDL) is cytotoxic to
vascular endothelium;2,6 in response, cells upregulate heme
oxygenase-1 (HO-1) and ferritin as a defense against such
toxicity.7–10 Heme oxygenase is a heme-degrading enzyme
that opens the porphyrin ring, producing biliverdin and
carbon monoxide and releasing iron.11 Three genes encode
for three isoenzymes for heme oxygenase. HO-1, identified as
the 32.8-kDa stress protein, is the form transcriptionally
inducible by a variety of agents, such as heme, oxidants, and
cytokines.12,13 Ferritin, a multimeric protein with a very high
capacity for storing iron, consists of 24 subunits of two types,
H- and L-ferritin.14 The importance of HO-1 and ferritin in
atherogenesis was highlighted by studies demonstrating
marked expression of both proteins and accumulation of
iron in atherosclerotic lesions.15–17 The upregulation of HO-1
and ferritin genes in endothelium possibly reflects cellular
responses to heme and heme-iron-generated lipid peroxida-
tion products.
Accelerated atherosclerosis occurs in chronic kidney
disease (CKD) patients on maintenance hemodialysis (HD)
treatment.18 Oxidative stress as a potential risk factor holds
particular importance in a HD population.19–21 Excessive
oxidation of lipoproteins was demonstrated by recent reports
in CKD patients,5,22–24 although no such evidence was found
in previous studies.25,26
In epidemiological studies, intake of antioxidants revealed
protective effects on the development and progression of
atherosclerosis.27 The protective role of antioxidants both on
LDL lipid peroxidation and on endothelial cell cytotoxicity
caused by oxidatively modified LDL has been demon-
strated.21 Oral vitamin E supplementation or dialysis with
vitamin E-modified membrane affords protection against
oxidative damage in patients treated with HD.28–30 Correc-
tion of vitamin C and ubiquinol deficiencies in CKD patients
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may potentiate the inhibitory effect of vitamin E on oxidative
modification of LDL.31
Low-molecular-weight components of blood plasma and
interstitial fluid compartment occurring in physiological and
pathological circumstances may alter free radical-mediated
endothelial cell damage and cellular reactions provoked by
LDL modification. The aim of the present work is to study
the modifying effect of the plasma ultrafiltrate of CKD
patients and healthy subjects on LDL lipid peroxidation in
vitro and on LDL-oxidation-provoked cellular reactions in
endothelial cells, such as the induction of cytotoxicity and the
upregulation of cell-protective HO-1 and ferritin genes.
RESULTS
Ultrafiltrate of plasma derived from a healthy subject (J)
prolonged DT at Vmax compared to the control (K), where
physiological saline was added instead of plasma ultrafiltrate
(84 vs 39 min) in heme-mediated LDL lipid peroxidation
measured by either conjugated diene formation (Figure 1a)
or degradation of heme (Figure 1b). Ultrafiltrate of a CKD
patient’s plasma taken just prior to HD treatment showed a
more pronounced retardation (m) of the reaction (DT at
Vmax¼ 120 min). This inhibitory effect was abolished by HD
treatment (n), and DT at Vmax dropped beneath the level of
ultrafiltrate of healthy volunteer (63 vs 84 min). To confirm
and quantitatively characterize this observation, we deter-
mined the increase in DT at Vmax of heme degradation during
heme-catalyzed LDL oxidation in the presence of plasma
ultrafiltrate of 15 healthy controls, 10 CKD patients before
and after HD treatment, and 13 CKD patients (stage 5)
without dialysis. As shown in Figure 1c, plasma ultrafiltrate
of CKD patients taken before dialysis treatment (HD-B)
exhibited a more pronounced inhibitory effect than that of
healthy subjects (control). A comparable inhibition was
observed using plasma ultrafiltrate of conservatively treated
patients with kidney failure (stage 5). Results clearly show
that, in the course of HD, plasma ultrafiltrate lost its capacity
to inhibit oxidation of LDL (HD-A).
In order to assess whether administration of heparin
during HD contributed to the loss of antioxidant potential of
ultrafiltrate, we administered 5000 IU of sodium heparin
intravenously to six healthy volunteers. Prior to and at 4 h of
heparin administration, we determined the prolongation of
DT at Vmax gained by samples of plasma ultrafiltrate.
Ultrafiltrate samples obtained before and after heparin
injection increased DT at Vmax to the same extent (2070 vs
36607416 and 37907442 s).
Since ox-LDL can threaten vascular endothelial cell
integrity, we tested whether the ultrafiltrate of plasma could
inhibit endothelial cytotoxicity provoked by oxidation of
lipoprotein (Figure 2). Indeed, plasma ultrafiltrate of healthy
individuals (control) attenuated the cytotoxicity derived
from heme-mediated LDL oxidation. Importantly, similar
protection was noted using plasma ultrafiltrate from CKD
patients treated conservatively (stage 5), or ultrafiltrate of
plasma received prior to dialysis (HD-B). In contrast, no
cytoprotection was observed if ultrafiltrate was derived from
postdialysis plasma of CKD patients (HD-A). To test whether
plasma ultrafiltrate can directly reduce the oxidative injury of
endothelium, we exposed cells to heme and then challenged
by hydrogen peroxide in the presence of plasma ultrafiltrate
of CKD patients received before and after HD. As demon-
strated in Figure 3, plasma ultrafiltrate derived prior
to dialysis (HD-B) inhibited cytotoxicity provoked by heme
and hydrogen peroxide. On the contrary, plasma ultrafiltrate
lost its potential to reduce oxidant injury in endothelium
during HD.
Exposure of endothelial cells to sublethal amounts of
ox-LDL markedly induces HO-1 and ferritin.9,32 Therefore,
we probed for expression of HO-1 messenger ribonucleic
acid (mRNA) as a sensitive marker for oxidative stress12 in
endothelium. Exposure of endothelium to ox-LDL induced
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Figure 1 | Effect of plasma ultrafiltrate derived from CKD patients
and healthy subjects on LDL lipid peroxidation. Conjugated diene
formation (a) and heme degradation (b) during heme-catalyzed
oxidation of LDL (200mg/ml) in the presence of plasma ultrafiltrate
derived from a healthy control (J) and a CKD patient before (m), and
after HD treatment (n) in comparison with the effect of heme
(5 mmol/l) and hydrogen peroxide (150 mmol/l) alone (K). (c) Increase
in DT at Vmax of heme degradation during heme- and hydrogen-
peroxide-initiated LDL oxidation in the presence of plasma ultra-
filtrate of CKD patients (n¼ 10) before (HD-B) and after (HD-A) HD
treatment, CKD patients (stage 5) without dialysis (n¼ 13), and
healthy controls (n¼ 15). *Po0.001 vs healthy control. wPo0.001 vs
HD-B.
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HO-1 mRNA (Figure 4a and b). Accompanying this mRNA
induction, heme oxygenase enzyme activity was also
markedly enhanced (Figure 4d). Plasma ultrafiltrate of a
CKD patient taken before HD (HD-B) prevented both HO-1
transcription (panels a and b) and a rise in enzyme activity
(panel d). In contrast, postdialysis plasma ultrafiltrate of the
same patient (HD-A) did not inhibit the LDL-oxidation-
provoked induction of HO-1 mRNA and enzyme activity.
Plasma ultrafiltrate derived either from a conservatively
treated CKD patient (stage 5) or from a healthy subject
(control) also prevented cells from upregulating HO-1
expression. Not surprisingly, exposure of endothelial cells
to ox-LDL led to increase in ferritin content (2677.5 vs
15.472.3 ng/mg cell protein). The increase in ferritin
synthesis after exposure of cells to ox-LDL was significantly
blunted by ultrafiltrate of predialysis plasma from the CKD
patient. This effect was also lost as we used ultrafiltrate of
postdialysis plasma (Figure 4e).
To confirm these findings, we performed dot blot analysis
for HO-1 mRNA using plasma ultrafiltrate of five CKD
patients before and after HD, five conservatively treated
patients with CKD, and five healthy volunteers (Figure 5).
Plasma ultrafiltrate of CKD patients taken before dialysis
treatment (HD-B) exhibited pronounced inhibitory effect on
LDL-oxidation-provoked induction of HO-1 mRNA. This
inhibition was lost after HD (HD-A). Plasma ultrafiltrate of
conservatively treated patients with kidney failure (Stage 5)
and healthy subjects (Control) prevented endothelial cells
from upregulating HO-1 gene transcription.
In order to find the molecular basis of the enhanced
inhibitory effect of plasma ultrafiltrate of CKD patients on
LDL lipid peroxidation, which was abolished by HD
treatment, we tested the modifying activity of numerous
retention solutes and plasma constituents in the heme-
mediated LDL lipid peroxidation system at concentrations
found in renal failure – namely, L-arginine, L-ascorbic acid,
bilirubin, creatinine, 2-furoic acid, guanidines (guanidine,
methylguanidine, b-guanidinopropionic acid, a-guanidino-
butyric acid), hippuric acid, indoles (3-indoxyl sulfate,
indoxyl b-D-glucuronide), myo-inositol, oxalic acid, poly-
amines (spermine, spermidine, putrescine, and cadaverine),
phenols (phenol, p-cresol), purines (uric acid, xanthine,
hypoxanthine), pyrimidine derivatives (cytidine, orotic acid,
thymine, pseudouridine), trimethylamine, and urea. Among
the examined compounds, only L-ascorbic acid, bilirubin,
p-cresol, 3-indoxyl sulfate, indoxyl b-D-glucuronide, phenol,
and uric acid had inhibitory effects on LDL lipid peroxida-
tion. Removal of uric acid from plasma by uricase did not
lead to the loss of inhibitory effect of plasma ultrafiltrate of
CKD patients; it retained about 30% of its antioxidant
activity.
To confirm the contribution of these compounds to the
inhibitory effect of plasma ultrafiltrate on LDL oxidation, we
measured the concentrations of p-cresol, phenol, 3-indoxyl
sulfate, and indoxyl b-D-glucuronide in plasma ultrafiltrate of
participants of the study, including healthy controls, CKD
patients on HD treatment (before and after HD), and
conservatively treated CKD patients. As shown in Table 1,
concentrations of 3-indoxyl sulfate, indoxyl b-D-glucuronide,
and p-cresol almost reached 10 mmol/l in plasma ultrafiltrate
of CKD patients before HD. During dialysis, concentrations
of all compounds dropped to the levels present in controls.
To compare the antioxidant potential of these retention
solutes, we determined DT at Vmax and Vmax values in heme-
catalyzed oxidation of LDL at 10 mmol/l concentration
(Table 2). The most potent inhibitor was p-cresol, followed
by bilirubin; oxidation of LDL did not occur within 4 h.
Phenol showed a characteristic decrease in Vmax of the
propagation phase of LDL lipid peroxidation, but it did not
influence DT at Vmax. We also assessed the direct cytopro-
tective effect of these molecules in endothelium. Endothelial
cells were exposed to heme and then challenged by hydrogen
peroxide in the presence of ascorbic acid, uric acid, bilirubin,
p-cresol, indoxyl-b-D-glucuronide, or 3-indoxyl-sulfate. As
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Figure 2 | Effect of plasma ultrafiltrate derived from CKD patients
and healthy subjects on endothelial cell cytotoxicity induced by
LDL oxidation. LDL (200 mg/ml) was oxidized with heme (5 mmol/l)
and hydrogen peroxide (75 mmol/l) in the presence or absence of
plasma ultrafiltrate derived from healthy controls (n¼ 15), CKD
patients (n¼ 10) before (HD-B) and after (HD-A) HD treatment, or
CKD patients (stage 5) without dialysis (n¼ 13). Cytotoxicity was
measured by MTT assay. All experiments were performed in
triplicates.
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Figure 3 | Cytotoxicity provoked by heme and hydrogen peroxide
in the presence of plasma ultrafiltrate of CKD patients treated
with HD. HUVECs were pretreated with heme (5 mmol/l) for 1 h,
which was followed by hydrogen peroxide (100 mmol/l) treatment
in the absence (empty bar) or presence (black bars) of ultrafiltrate
(7.5 v/v%) derived from CKD patients before (HD-B) and after (HD-A)
HD treatment. The figure shows mean values of ultrafiltrate from
five patients measured in triplicates.
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shown in Figure 6, ascorbic acid, uric acid, bilirubin, p-cresol,
indoxyl-b-D-glucuronide, and 3-indoxyl-sulfate provided
protection at concentrations similar to that observed in
CKD patients before HD.
DISCUSSION
Endothelial cell damage and dysfunction were observed as
important components of atherosclerosis in patients with
CKD on maintenance HD.33–35 Data regarding the decreased
antioxidant defense of uremic patients to explain free-
radical-mediated complications and accompanied diseases
as accelerated atherosclerosis have accumulated. On the
contrary, plasma total peroxyl radical-trapping antioxidant
potential (TRAP) was reported to be increased in the plasma
of HD patients and was related to the presence of high uric
acid levels.20,36,37 At the same time, HD treatment was
reported to significantly decrease the plasma total antioxidant
capacity.38
These previous studies prompted us to examine the
comprehensive antioxidant capacity of plasma ultrafiltrate
from CKD patients on oxidative modification of LDL.
Employing the adapted heme-mediated LDL oxidation
method, a sensitive marker for assessing the antioxidant
potential of water or lipid-soluble compounds,2,3,39 we found
that plasma ultrafiltrate of CKD patients has an enhanced
antioxidant effect on oxidative modification of LDL com-
pared to healthy controls, and it exhibits a dramatic drop
under the physiological level during HD treatment. Further-
more, we demonstrate that endothelial cell cytotoxicity
provoked by LDL oxidation as well as the upregulation of
redox-sensitive HO-1 and ferritin genes in response to
oxidative stress of LDL are blunted by plasma ultrafiltrate of
CKD patients and healthy subjects. Inhibition of these
endothelial cell reactions in response to oxidation of LDL
diminishes during HD treatment. The decreased antioxidant
capacity of ultrafiltrate after HD occurs as a consequence of
the intradialytic removal of L-ascorbic acid, uric acid,
bilirubin, 3-indoxyl sulfate, indoxyl-b-D-glucuronide,
p-cresol, and phenol.
We tried to ascertain which constituent of plasma
ultrafiltrate from hemodialyzed patients is responsible for
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Figure 4 | Effect of plasma ultrafiltrate derived from CKD patients and healthy subjects on LDL-oxidation-provoked induction of HO-1
and ferritin in endothelial cells. (a) For HO-1 mRNA Northern analysis, endothelial cells were incubated with LDL (50 mg/ml) – after it was
oxidized by heme (1.25mmol/l) and hydrogen peroxide (18.75 mmol/l) to reach the propagation phase of lipid peroxidation – alone (oxLDL) or in
the presence of plasma ultrafiltrate of a CKD patient before (HD-B) or after HD (HD-A), a CKD patient (stage 5) without dialysis, and a healthy
subject (control) in comparison with untreated control (NT) as described in ‘Materials and Methods’. (b) Densitometry tracing of HO-1 mRNA
bands expressed as arbitrary OD units. (c) The corresponding S28 and S18 ribosomal RNA of Northern blot in panel a. (d) Heme oxygenase
enzyme activity measured 8 h after exposure of endothelial cell monolayers. (e) Ferritin content 16 h after treatment of endothelial cells.
(a–c) Representative of three different experiments. (d, e) Results are expressed as mean7s.d. of three independent experiments performed
in duplicate.
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Figure 5 | Expression of HO-1 in endothelium induced by LDL
oxidation in the presence of plasma ultrafiltrate derived from
CKD patients and healthy subjects. For HO-1 mRNA dot blot
analysis, LDL (50 mg/ml) was oxidized by heme (1.25mmol/l) and
hydrogen peroxide (18.75 mmol/l) to reach the propagation phase of
lipid peroxidation, and then added to endothelial cells alone (oxLDL)
or in the presence of plasma ultrafiltrate of CKD patients before
(HD-B) or after (HD-A) HD, CKD patients (stage 5), and healthy
subjects (control) as described in ‘Materials and Methods’. NT
represents nontreated cells.
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the attenuation of heme-mediated oxidative modification of
LDL and oxidative endothelial cell damage. In our studies,
several uremic toxins were tested in vitro. Among them only
L-ascorbic acid, uric acid, bilirubin, 3-indoxyl sulfate,
indoxyl-b-D-glucuronide, p-cresol, and phenol proved to be
efficient. Importantly, after removal of uric acid by uricase,
30% of antioxidant activity of plasma ultrafiltrate is
preserved, suggesting the presence of antioxidants in plasma
other than uric acid. As we compared the molecules
according to the mechanism of action on heme-mediated
oxidative modification of LDL (e.g., their effect on DT at
Vmax and Vmax), differences in the strength and in the pattern
of antioxidant action were detected. According to the latter,
the prolongation of the initiation phase resulting in increased
DT at Vmax (ascorbic acid, uric acid, bilirubin, indol
derivatives, and p-cresol) and the retardation of propagation
phase resulting in decreased Vmax values (bilirubin, phenol)
of LDL lipid peroxidation were observed. Dominantly, the
initiation phase is altered by the addition of plasma
ultrafiltrate to the LDL lipid peroxidation system. The
prolongation of initiation phase is accepted to be the
consequence of the regeneration of oxidized tocopherol
within LDL by the added redox active materials. The
common feature in the chemical structure of effective
compounds (ascorbic and uric acid, phenol, and p-cresol)
is that all contain free hydroxyl group(s) and double bonds
(benzene ring). All of these structures are known to possess
antioxidant and/or radical trapping capacity.
Indole derivatives absorbed from our food and produced
by the intestinal flora from tryptophan are retained in case of
renal insufficiency.40 For its high protein-binding and tubular
secretion, indoxyl sulfate alters the pharmacokinetic proper-
ties of drugs; it inhibits thyroxin deiodination and may be
responsible for acceleration of glomerular sclerosis.40 We
found that, in addition to these pathophysiological effects,
3-indoxyl sulfate and indoxyl b-D-glucuronide may serve
as effective antioxidants of LDL lipid peroxidation. Moreover,
3-indoxyl sulfate is retained during HD treatment.40,41 In
accordance with previous findings,36,40–43 we also demon-
strated that concentrations of 3-indoxyl sulfate and indoxyl-
b-D-glucuronide, as well as p-cresol and phenol, are elevated
in CKD patients, and they are removed during HD treatment.
The protective antioxidant effect of plasma ultrafiltrate
from CKD patients was demonstrated not only in LDL
suspension but also in human endothelial cell cultures.
Inhibition of endothelial cell cytotoxicity induced by
heme-catalyzed LDL oxidation develops in the presence of
plasma ultrafiltrate from CKD patients treated conservatively,
and a similar protection is noted using ultrafiltrate of
plasma received prior to dialysis. Importantly, plasma
ultrafiltrate derived from postdialysis plasma of CKD subjects
fails to exhibit endothelial cell protection against oxidatively
modified LDL. We also observed a direct cytoprotective
effect of plasma ultrafiltrate and its constituents – ascorbic
Table 1 | Concentrations of p-cresol, phenol, indoxyl-b-D-glucuronide, and 3-indoxyl sulfate in the plasma ultrafiltrate
of healthy controls, CKD patients in stage 5 without HD, and CKD patients on HD (before and after hemodialysis)
CKD patients on HD
Control CKD patients stage 5 without HD Before-HD After-HD
15 13 10 10
p-Cresol (mmol/l) 0.41470.552 1.92870.485 5.5674.01 0.77570.672
Phenol (mmol/l) 0.49270.11 0.90570.383 0.92770.248 0.76170.125
3-Indoxyl sulfate (mmol/l) 2.5171.36 4.8472.55 9.88710.65 2.3970.62
Indoxyl-b-D-glucoronide (mmol/l) 3.0971.28 4.2772.73 9.4979.51 3.8971.16
Table 2 | Kinetic parameters of heme-mediated LDL oxidation
in the presence of different plasma constituents at concen-
tration of 10 lmol/l (mean7s.d.)
Compounds DT at Vmax (s) Vmax (mOD/min)
Control 3780760 5.970.11
L-Ascorbic acid 64807159 5.2370.43
Uric acid 53207434 6.2570.57
Bilirubin 10 6207676 1.8370.21
3-Indoxyl sulfate 504076 5.1770.11
Indoxyl-b-D-glucuronide 4480735 4.6870.14
p-Cresol 414 400 Not applicable
Phenol 3820792 3.9670.19
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Figure 6 | Endothelial cell cytotoxicity induced by heme and
hydrogen peroxide in the presence of retention solutes. HUVECs
were pretreated with heme (5 mmol/l) for 1 h, then challenged by
hydrogen peroxide (100 mmol/l) in the presence of ascorbic acid
(400 mmol/l), uric acid (400 mmol/l), bilirubin (10 mmol/l), p-cresol
(10mmol/l), indoxyl-b-D-glucuronide (10mmol/l), or 3-indoxyl-sulfate
(10mmol/l). The empty bar represents cytotoxicity of hydrogen
peroxide alone. The figure shows mean7s.d. of three independent
experiments performed in triplicates. *Po0.001.
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acid, uric acid, bilirubin, p-cresol, indoxyl-b-D-glucuronide,
or 3-indoxyl-sulfate – in endothelium challenged by heme
and hydrogen peroxide, which was lost during dialysis.
The loss of cytoprotection exerted by plasma ultrafiltrate
might represent a threat to vascular endothelial cell integrity
as activation of inflammatory cells occurs during HD
treatment.
We have shown earlier that endothelial cells exposed to
sublethal concentration of ox-LDL increase the expression of
HO-1 as well as ferritin, and this induction involves LDL-
associated hydroperoxides.3,32 The present studies demon-
strate that expression of HO-1 and ferritin in endothelial cells
induced by LDL lipid peroxidation is blocked by plasma
ultrafiltrate taken before dialysis, and released when ultra-
filtrate gained after HD. In addition to being a marker of
exposure to oxidizing events, HO-1 and ferritin have been
demonstrated to be cytoprotective in various models.8,10,32
Iron-driven oxidative injury of endothelial cells, such as
cytotoxicity provoked by ox-LDL or inflammatory cells, can
be prevented by induction of ferritin synthesis.7,15 The
protective role of ferritin against iron-driven oxidative
damage is attributable to the high sequestering capacity for
inorganic iron and ferroxidase activity of its H chain.7
Intracellular ferritin was shown to abolish iron-catalyzed
oxidation of LDL, and increased expression of HO-1 in
endothelial cells was demonstrated to inhibit monocyte
transmigration induced by ox-LDL.44 Conversion of heme to
biliverdin and bilirubin45,46 was revealed to protect neurons
against oxidative stress. Carbon monoxide produced during
the degradation of heme has attracted a great deal of interest
on its potential function in regulating vascular tone and
inflammation.13,47 Nath et al.48 provided the first in vivo
evidence in an animal model that induction of HO-1 coupled
to ferritin synthesis is a rapid protective antioxidant response;
induction of HO-1 and ferritin protects rats against
rhabdomyolysis-induced renal failure. Induction of HO-1
and ferritin was also shown to be important for xenograft
survival.49,50 HO-1 deficiency in a human being was
accompanied by both endothelial cell injury and severe
atherosclerosis.51 Similar damage to endothelium, as well as
hepatic and renal tubular cytotoxicity, has been observed in
transgenic knockout mice deficient in HO-1.52
Oxidative modification of LDL and endothelial cell
damage provoked by LDL oxidation, as a result of depletion
of L-ascorbic acid, uric acid, bilirubin, 3-indoxyl sulfate,
indoxyl-b-D-glucuronide, p-cresol, and phenol in blood
during HD, might represent an immediate threat to the
vasculature. The adaptation to such an insult may require
many hours in order to gain defense mechanisms (i.e.
upregulation of HO-1 and ferritin synthesis), leaving cells
susceptible to oxidative damage by the end of HD. In a
rapidly undulating oxidative environment of endothelium,
the delayed adaptation may not be entirely sufficient to
prevent lipid peroxidation and endothelial cell injury in
uremic patients on HD, resulting in an enhanced risk for
atherosclerosis.
MATERIALS AND METHODS
Patients and ultrafiltration of plasma
Blood was drawn in 1 mg/l ethylenediaminetetraacetate (EDTA)
from 10 CKD patients treated with HD (five males and five females,
mean age: 56.275.6 years), 13 CKD patients with kidney failure
(stage 5) treated conservatively without kidney replacement therapy
(plasma creatinine¼ 446771 mmol/l, GFR¼ 11.872.5 ml/min cal-
culated by a quadratic GFR equation53) (seven males and six
females, mean age: 54.374.8 years), and 15 healthy volunteers
(eight males and seven females, mean age: 50.175.4 years). The
patients were placed on HD therapy of three 4-h sessions weekly,
using a 1.2-m2 polysulfone capillary dialyzer (Hemoflow F60(S)
High Flux, Fresenius Medical Care AG, Bad Homburg, Germany)
and bicarbonate dialysis solution containing 1.5 mmol/l of calcium.
After an initial bolus dose of 1000 U, heparin was administered using
a constant infusion method with an infusion rate of 500 U/h. The
Kt/V ratio was 1.2770.3. None of the patients involved in the study
had evidence of liver disease, heart failure, thyroid disorder,
malignant disease, or infectious diseases. Patients on HD received
recombinant human erythropoietin (NeoRecormon, Roche Phar-
maceuticals, Basel, Switzerland) delivered subcutaneously
(520071033 U/week), and iron supplementation (62.5 mg ferric
gluconate/14 days) (Ferrlecit, Aventis Pharma, Frankfurt, Germany).
Blood samples were taken immediately before (HD-B) and after
(HD-A) treatment on the second dialysis of the week.
Plasma was separated by centrifugation at 2000 g for 15 min
at 41C and then ultrafiltration of plasma was performed using
the Ultrafree-4 (Millipore Corp., Bedford, MA, USA) centrifugal
filter unit (7500 g, 15 min at 41C) containing Biomax-5 polyamide
membrane with a nominal molecular weight limit of 5000 Da.
All patients and volunteers gave their informed consent, which met
with the rules of the Ethical Committee of the University of
Debrecen.
HPLC measurements
In plasma ultrafiltrate of controls, HD patients before and after HD,
and patients treated by conservative therapy, p-cresol, phenol, 3-
indoxyl sulfate, and indoxyl-b-D-glucoronide were determined by
HPLC (Merck-Hitachi). All compounds were determined by
fluorescence detection (Merck-Hitachi, model type of F 1050). p-
Cresol and phenol were measured using an excitation wavelength of
260 nm and an emission wavelength of 305 nm after extraction.
Ultrafiltrate was acidified by 6 mol/l HCl and extracted with
ethylacetate. The extract was evaporated to dryness under nitrogen
stream at room temperature. Samples were injected to a reverse-
phase C18 column (4.6 150 mm, 5 mm particle size) (Merck Co.,
Darmstadt, Germany). Mobile phase consisted of distilled water/
acetonitrile (70/30 v/v) and flow rate was 1 ml/min.40 Indoxyl-b-D-
glucoronide and 3-indoxyl sulfate were determined using an
excitation wavelength of 280 nm and an emission wavelength of
400 nm. Ultrafiltrates were injected directly to a reverse-phase C18
column (4.6 150 mm, 5mm particle size) (Merck, Darmstadt,
Germany). Mobile phase consisted of 10 mmol/l ammonium
formate/methanol (95/5 v/v). Flow rate was 1 ml/min.41 Calibration
curves were performed using analytical grade compounds. All
reagents were HPLC grade and were purchased from Merck Co.
(Darmstadt, Germany).
Isolation of LDL
LDL was isolated by density gradient ultracentrifugation39 from
plasma derived from EDTA (1 mg/ml)-anticoagulated venous blood
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of healthy volunteers. The LDL fraction was dialyzed against EDTA
(30mmol/l) containing saline buffered by HEPES (3 mmol/l, pH 7.4)
for 3 2 h. Protein concentration was determined by BCA protein
assay (Pierce, Rockford, IL, USA). Purity of the LDL fraction was
checked by agarose gel electrophoresis.
Oxidation of LDL39
In lipid peroxidation assay, LDL (200 mg/l) was incubated with heme
(5mmol/l) and hydrogen peroxide (150 mmol/l) at 371C buffered
with HEPES (10 mmol/l, pH 7.4) in the presence or absence of
plasma ultrafiltrate (7.5 v/v%). In heme-catalyzed oxidation of LDL,
lipid peroxidation was monitored by measuring conjugated diene
formation and heme degradation.2 The formation of conjugated
dienes was determined spectrophotometrically at 234 nm. The
kinetics of heme disappearance was monitored spectrophotome-
trically as well at 405 nm in a computer-assisted Microplate Reader
(Bio-Tek Instruments, Winooski, VT, USA). The maximal velocity of
the propagation phase of LDL lipid peroxidation, Vmax, and the time
passed till the maximal velocity, DT, at Vmax were measured. To
determine the antioxidant or pro-oxidant potential of uremic
retention materials at uremic and physiological concentrations,
changes in DT at Vmax and Vmax were measured.
Endothelial cell isolation and culture
As in our previous studies,3,8 human umbilical vein endothelial cells
(HUVECs) were removed from human umbilical veins by exposure
to dispase (0.2% for 6 h at 41C), and cultured in medium 199
containing 15% fetal calf serum, penicillin (100 U/ml), streptomycin
(100 U/ml), and heparin (5 U/ml) supplemented with L-glutamine,
sodium pyruvate, and endothelial cell growth factor. Endothelial
cells were identified by their morphology, the presence of von
Willebrand factor-related antigen. The cell cultures were studied to
passage 3 within 48 h of reaching confluence.
Endothelial cell cytotoxicity assay
Confluent endothelial cell monolayers were washed three times
with Hank’s balanced salt solution (HBSS) and were treated
with a reaction mixture of LDL (200 mg/ml), heme (5 mmol/l),
and H2O2 (75mmol/l) in the presence or absence of ultrafiltrate
(7.5 v/v%) derived from healthy volunteers, CKD patients
on HD before and after treatment, or conservatively treated CKD
patients (stage 5). To measure the direct antioxidant potential of
ultrafiltrate, endothelial cells were washed three times with HBSS,
and then pretreated with heme (5mmol/l) for 1 h. Cytotoxicity was
provoked by hydrogen peroxide (100 mmol/l) in the absence or
presence of ultrafiltrate derived from CKD patients before or after
HD. To test the direct antioxidant potential of uremic retention
solutes, endothelial cells were washed three times with HBSS, and
were pretreated with heme (5 mmol/l). Cytotoxicity was induced by
the addition of hydrogen peroxide (100 mmol/l) alone or in the
presence of ascorbic acid (400 mmol/l), uric acid (400 mmol/l),
bilirubin (10 mmol/l), p-cresol (10mmol/l), 3-indoxyl-sulfate
(10mmol/l), or indoxyl-b-D-glucuronide (10mmol/l). In all experi-
ments, after a 2–4-h incubation, test solutions were removed and
MTT assay3 was performed.
Heme oxygenase enzyme activity assay
Heme oxygenase activity in endothelial cell microsomes was
measured by bilirubin generation.7 Endothelial cells grown in 10-
cm-diameter tissue culture dishes were treated with LDL samples in
media 199 for 60 min, followed by 8-h incubation with complete
media alone. Endothelial microsomes were incubated with hepatic
cytosol (2 mg), hemin (20 mmol/l), glucose-6-phosphate dehydro-
genase (0.2 U), and NADPH (0.8 mmol/l). The formed bilirubin was
extracted with chloroform and a D optical density (OD) of 464 and
530 nm was measured (extinction coefficient 40 M1 cm1). Heme
oxygenase activity is expressed as pmol bilirubin formed/mg cell
protein/60 min.
Ferritin assay
Endothelial cell ferritin content was measured after treatment of
cells with control medium or test solutions in HBSS for 60 min.
After a further 16 h of incubation in complete medium, the cells
were solubilized3 and analyzed for ferritin content using the IMx
ferritin enzyme immunoassay (Abbott Laboratories, Abbott Park,
IL, USA). The results are expressed as ng of ferritin/mg of cell
protein.
HO-1 mRNA analysis
Heme oxygenase mRNA content was analyzed in confluent
endothelial cells grown in 10-cm-diameter tissue culture dishes or
six-well plates. Endothelial cell monolayers were washed three times
with HBSS, and treated with the same reaction mixture we used at
cytotoxicity assay, but samples were diluted by four-fold with HBSS.
After a 60-min incubation, LDL test solutions were replaced with
LDL-free media for 4 h. Endothelial cell RNA was isolated by the
RNAzol method (TEL-TEST Inc., Friendswood, TX, USA). For
mRNA Northern analysis, 15 mg of total RNA of endothelial cells
cultured in 10-cm-diameter dishes was electrophoresed and
transfered to a nylon membrane. The positions of 28S and 18S
ribosomal RNA and the equal loading of samples were checked by
ethidium bromide staining. For dot blot, 5 mg of the total RNA of
endothelium cultured in six-well plates was blotted onto a nylon
membrane and crosslinked by UV irradiation. The membranes were
then hybridized at 651C with biotin-labeled (Bioprime DNA
Labeling System) (Synovis Life Technologies Inc., St Paul, MN,
USA) complementary DNA probes for human HO-1.3,7 Biotinylated
probes hybridized to nucleic acids were detected by a chemilumi-
nescent detection system (Photogene System 2.0) (Synovis Life
Technologies Inc.). Autoradiographs were quantified by computer-
assisted videodensitometry.
Statistical analysis
Data are expressed as mean and standard deviation. The paired or
unpaired Student’s t-test and analysis of variance were used
wherever applicable.
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